國家衛生研究院 NHRI:Item 3990099045/9331

NHRI > National Institute of Infectious Diseases and Vaccinology > Shu-Chen Kuo > Periodical Articles > Item 3990099045/9331

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/9331

Title:	A retrospective study of the incidence, clinical characteristics, identification, and antimicrobial susceptibility of bacteremic isolates of Acinetobacter ursingii
Authors:	Chiu, CH;Lee, YT;Wang, YC;Yin, T;Kuo, SC;Yang, YS;Chen, TL;Lin, JC;Wang, FD;Fung, CP
Contributors:	Division of Infectious Diseases
Abstract:	Background: Acinetobacter ursingii bacteremia is rarely reported. We investigated the incidence and clinical features of A. ursingii bacteremia, performance of the identification system, and antimicrobial susceptibility of the isolates. Acinetobacter ursingii bacteremia patients were compared with A. baumannii bacteremia patients. Methods: In this 9-year retrospective study, A. ursingii was identified using 16S rRNA and 16S-23S rRNA internal transcribed spacer sequence analysis. The performances of the Vitek 2, Phoenix, and matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometer systems for identifying isolates were tested. Pulsed-field gel electrophoresis (PFGE) was used to determine the clonality of the isolates. The minimal inhibitory concentrations of the antimicrobials were determined using the Vitek 2 system. Results: Nineteen patients were identified. Acinetobacter ursingii was noted in 1.5-5.2% of all Acinetobacter bacteremia cases. For the PFGE analysis, two isolates had smeared DNA, two had 93% similarity, and 15 had similarity <80%. Among 16 patients with complete medical records, 10 (62.5%) had no identifiable source of A. ursingii bacteremia. Most patients (n=12) had underlying malignant disease. Patients with A. ursingii bacteremia had lower Acute Physiology and Chronic Health Evaluation II scores than those with A. baumannii bacteremia (median [interquartile range], 17.1 [10.0-24.7] vs. 24.9 [14.6-35.1]). Patients with A. ursingii bacteremia were also less likely admitted to the intensive care unit than patients with A. baumannii bacteremia (18.8% vs 63.5%, p value<0.01). About half of the patients with A. ursingii (50.8%) and A. baumannii bacteremia (62.5%) had received inappropriate antimicrobial therapy within 48h after bacteremia onset. However, patients with A. ursingii bacteremia had significantly lower 14-day (6.25% vs 29.8%, p value=0.04) and 28-day mortality rates (6.25% vs 37.3%, p value=0.02) than patients with A. baumannii bacteremia. Nine isolates (47.4%) were correctly identified as A. ursingii and the other 10 isolates (52.6%) were incorrectly identified as A. lwoffii by the Vitek 2 system. The Phoenix system incorrectly identified all 19 isolates. The MALDI-TOF mass spectrometer system correctly identified all 19 isolates. All the A. ursingii isolates were resistant or showed intermediate susceptibility to ceftriaxone and ceftazidime, but were susceptible to levofloxacin and imipenem. Conclusions:Acinetobacter ursingii is a rare pathogen that mostly caused primary bacteremia in patients with malignancies. Patients with A. ursingii bacteremia had significantly lower disease severity and mortality ratesthan patients with A. baumannii bacteremia.
Date:	2015-09-30
Relation:	BMC Infectious Diseases. 2015 Sep 30;15:Article number 400.
Link to:	http://dx.doi.org/10.1186/s12879-015-1145-z
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1471-2334&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000362252200009
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84942571400
Appears in Collections:	[Shu-Chen Kuo] Periodical Articles

Files in This Item:

File	Description	Size	Format
SCP84942571400.pdf		620Kb	Adobe PDF	551	View/Open

Loading...